Richard Scolyer's Farewell Letter Marks Death at 59 After 3-Year Glioblastoma Battle
Updated
Updated · Sydney Morning Herald · Jun 7
Richard Scolyer's Farewell Letter Marks Death at 59 After 3-Year Glioblastoma Battle
1 articles · Updated · Sydney Morning Herald · Jun 7
Summary
Professor Richard A. Scolyer’s final open letter was published after his death on June 7, closing a three-year public battle with glioblastoma that began with his May 2023 diagnosis.
In the letter, the 2024 Australian of the Year said he stayed public about his illness to show what families endure and to push brain-cancer research forward.
Scolyer highlighted a 35-year career in cancer care and research, including more than 1,000 publications, leadership roles with global cancer bodies, and work that helped lift advanced melanoma survival through immunotherapy.
He also pointed to his own experimental treatment—based on melanoma science he helped develop—and urged patients to join trials while calling on government and the public to keep funding medical research.
His farewell framed that advocacy as his legacy: using his terminal diagnosis to generate data, raise awareness and leave a stronger platform for future brain-cancer patients.
Can one man's revolutionary self-experiment truly become a cure for the world's deadliest brain cancer?
Beyond one man's fight, what emerging tech could finally defeat incurable glioblastoma?
As miracle cancer cures emerge, how do we solve the deadly inequality in who gets access?
Professor Richard Scolyer’s Legacy: Pioneering Experimental Immunotherapy in Glioblastoma and Transforming Brain Cancer Research
Overview
Professor Richard Scolyer, a renowned Australian pathologist, passed away on June 7, 2026, after a courageous battle with glioblastoma. Despite his diagnosis, he defied the grim prognosis and continued to contribute to medical research, even in his darkest hour. Scolyer openly shared his journey, including the progression of his brain tumour and its impact on his health. He transformed his personal fight into a pioneering effort, becoming the first to test an experimental immunotherapy treatment for glioblastoma. His legacy is marked by his dedication to advancing science and inspiring hope for future brain cancer patients.